← All trials
NCT06020066
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2023
- Primary completion
- Aug 10, 2028
- Completion date
- Aug 10, 2029
- First posted
- Aug 31, 2023
- Last posted
- Aug 31, 2023
- Enrollment
- 202
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Jiangnan UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Fudan UniversityReponsible party - principal investigator
- Ningxia Medical UniversityOverall official - principal investigator
- Wuhan UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Jiangsu Cancer Institute & HospitalOverall official - principal investigator
- Jilin Provincial Tumor HospitalOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Ningbo No. 2 HospitalOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Shandong UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Guizhou Medical UniversityOverall official - principal investigator
- Nantong UniversityOverall official - principal investigator
- Dalian Medical UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Jiangsu Cancer Institute & HospitalOfficial
- Central South UniversityOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Fudan UniversityOfficial
- Guizhou Medical UniversityOfficial
- Jilin Provincial Tumor HospitalOfficial
- Jiangnan UniversityOfficial
- Chongqing Medical UniversityOfficial
- Southern Medical UniversityOfficial
- People's Liberation Army of ChinaOfficial
- Ningxia Medical UniversityOfficial
- Peking UniversityOfficial
- Fudan UniversitySponsor investigator
- Huazhong University of Science and TechnologyOfficial
- Huazhong University of Science and TechnologyOfficial
- Nantong UniversityOfficial
- Dalian Medical UniversityOfficial
- Wuhan UniversityOfficial
- Tianjin Medical UniversityOfficial
- Ningbo No. 2 HospitalOfficial
- Shandong UniversityOfficial
- Fujian Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.